Shell Asset Management Co. Increases Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Shell Asset Management Co. grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 45.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,975 shares of the company’s stock after purchasing an additional 9,403 shares during the quarter. Shell Asset Management Co.’s holdings in Intellia Therapeutics were worth $350,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after acquiring an additional 562,249 shares during the period. Regeneron Pharmaceuticals Inc. bought a new stake in Intellia Therapeutics during the 4th quarter worth approximately $43,177,000. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after buying an additional 45,930 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Intellia Therapeutics by 36.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company’s stock valued at $23,042,000 after buying an additional 528,962 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on NTLA. Truist Financial dropped their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Guggenheim decreased their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a report on Monday, May 12th. Citigroup reduced their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating for the company in a report on Friday, May 9th. HC Wainwright assumed coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 target price for the company. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.90.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $8.50 on Monday. The business has a 50-day moving average of $7.99 and a 200 day moving average of $10.75. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The stock has a market capitalization of $880.46 million, a price-to-earnings ratio of -1.56 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analysts’ expectations of $11.39 million. During the same quarter last year, the business earned ($1.12) earnings per share. The business’s revenue was down 42.6% compared to the same quarter last year. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.